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Abstract
Inflammation, insoluble protein deposition and neuronal cell loss are important features in the Alzheimer’s disease (AD)
brain. To investigate the regulatory genes responsible for the neuropathology in AD, we performed microarray analysis with
APPV717I-CT100 transgenic mice, an animal model of AD, and isolated the S100a9 gene, which encodes an inflammation-
associated calcium binding protein. In another AD animal model, Tg2576 mouse brain, and in human AD brain, induction of
S100a9 was confirmed. The endogenous expression of S100a9 was induced by treatment with Ab or CT peptides in a
microglia cell line, BV2 cells. In these cells, silencing study of S100a9 showed that the induction of S100a9 increased the
intracellular calcium level and up-regulated the inflammatory cytokines (IL-1b and TNFa) and iNOS. S100a9 lentiviral short
hairpin RNA (sh-S100a9) was injected into the hippocampus region of the brains of 13-month-old Tg2576 mice. At two
months after injection, we found that knockdown of S100a9 expression had improved the cognition decline of Tg2576 mice
in the water maze task, and had reduced amyloid plaque burden. These results suggest that S100a9 induced by Ab or CT
contributes to cause inflammation, which then affects the neuropathology including amyloid plaques burden and impairs
cognitive function. Thus, the inhibition of S100a9 is a possible target for AD therapy.
Citation: Ha T-Y, Chang K-A, Kim J, Kim H-S, Kim S, et al. (2010) S100a9 Knockdown Decreases the Memory Impairment and the Neuropathology in Tg2576 Mice,
AD Animal Model. PLoS ONE 5(1): e8840. doi:10.1371/journal.pone.0008840
Editor: Thierry Ame ´de ´e, UMR CNRS 5226 - Universite ´ Bordeaux 2, France
Received October 14, 2009; Accepted January 4, 2010; Published January 21, 2010
Copyright:  2010 Ha et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was financially supported by National Creative Research Initiative Grant (2006-2009) from Korea Ministry of Education, Science and
Technology, in part by the National Research Foundation of Korea grant funded by the Korea government (2009-0086201), in part by WCU program (R33-10167)
of the ministry of education, Science and Technology, and in part by the Conversing Research Center Program through the National Research Foundation of
Korea funded by the Ministry of Education, Science and Technology (2009-0082268). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: yhsuh@snu.ac.kr
. These authors contributed equally to this work.
Introduction
Alzheimer’s disease (AD) is characterized clinically by global
cognitive dysfunction and neuropathologically by an age-depen-
dent formation of b amyloid (Ab)-containing senile plaques,
usually surrounded by reactive astrocytes, activated microglia
and dystrophic neurites, and intracellular neurofibrillary tangles
(NFTs) [1,2,3].
Neuroinflammation is also one of the prevalent features of AD
brains, along with insoluble protein deposition and neurodegen-
eration [4,5]. To investigate the regulatory genes responsible for
the neuroinflammation related to AD, we performed microarray
analysis with APPV717I-CT100 Tg (CT-Tg) mice, an animal model
of AD. CT-Tg mice over-express 100 amino acids of C-terminal
fragment of amyloid precursor protein (CT) with London
mutation, which leads to extensive neuronal degeneration in the
hippocampal area [6], cognitive impairment [7] and destruction of
long-term potentiation (LTP) [8]. Several genes were significantly
upregulated in these mice, and we focused on the S100a9 gene,
whose expression was markedly increased.
S100a9 is an inflammation-associated calcium binding protein
belonging to the S100 family [9,10]. Up-regulated S100a9 in
reactive microglia [9,11] activates the p38 mitogen-activated
protein kinase (MAPK) cascade, NF-kB or calcium-dependent
signal transduction [12] and is involved in the production of
proinflammatory cytokines, the regulation of neurite extension,
cell migration, and calcium homeostasis [13]. Neurological
diseases such as cerebral ischemia [14], traumatic brain injury
[15] and AD [16] have been reported to be associated with altered
expression/function of the S100 family members [17]. Recently,
S100a9 was found to be increased within neuritic plaques and
reactive glia and was proposed to participate in the inflammation
of the AD pathogenesis [16]. However, the detailed molecular
mechanism of these pathological events remains unknown.
Here, we provide evidence that S100a9 gene is significantly up-
regulated in the brains of AD animal models, Tg2576 and CT-Tg
mice, and of human AD patients. CT as well as Ab has been
known to be involved in the pathogenesis of AD [18,19,20,21].
Treatment with Ab or CT peptides induced S100a9 in a dose-
dependent manner. Our data show that S100a9 is involved in the
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8840production of inflammatory cytokines induced by Ab or CT in
BV2 cells. Moreover, data from knockdown experiments show
that S100a9 might be responsible for the neurodegeneration and
cognitive deficits in Tg2576 mice.
Results
S100a9 Is Induced in the Brains of Alzheimer’s Disease
Animal Models and Human AD Patients
To select candidate genes related to AD, microarray analysis
was performed with the total RNA of the hippocampus of CT-Tg
and age-matched wild-type (WT) mice. Some of the gene
microarray results were validated by RT-PCR and western blot,
and the S100a9 gene was selected for further studies. As seen in
Figure 1A, mRNA levels of S100a9 were induced in the cortex and
hippocampus of CT-Tg brains. On western blot and immunohis-
tochemical analyses, S100a9 protein was significantly increased in
the cortex and in the hippocampus of CT-Tg brains compared
with that in region-matched WT brains (Figures 1A-C). In Tg2576
mice overexpressing Swedish type APP (sweAPP) [22,23], S100a9
was also significantly increased in the cortex and hippocampal
regions of the brain compared with that in WT brains (Figure 1C).
To determine the physiological significance of the increased
S100a9 levels in the brains of CT-Tg and Tg2576 mice, we
examined the level of S100a9 in the brains of human AD patients
and age-matched controls. AD brain sections (Figure 1C) and total
lysates (Figures S1A&B) exhibited increased expression of S100a9
compared to control brains.
Figure 1. S100a9 was induced in the brains of CT-Tg, Tg2576 mice and Human AD patients. (A) mRNA levels of S100a9 were measured in
the cortex and hippocampus of CT-Tg and age-matched WT mice brains by RT-PCR. Actin was used as a loading control. The protein level of S100a9
was checked by western blotting. Tubulin was used as a loading control. (B) S100a9 expression was normalized with that of tubulin for quantification
(n=5). Results are presented as the means 6 SEM. *P ,0.05, **P,0.01 by Student’s t-test. (C) Immunoreactivities of S100a9 were examined in the
cortex, hippocampus [CA3, dentate gyrus (DG)] of 11-month-old CT-Tg, of 11-month-old Tg2576 and of human AD brains compared with normal age-
matched brains. Scale bar represents 100 mm.
doi:10.1371/journal.pone.0008840.g001
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Up-regulation of S100a9 expression was detected in the brains of
CT-Tg and Tg2576 mice, as well as in AD brains, which might be
related to over-produced Ab and CT. In the brains of CT-Tg mice
used in the microarray analysis, S100a9 was highly expressed in
CD11b-positive microglia (Figure 2A), consistent with the report
that S100a9wasup-regulatedinreactive microglia[9].To elucidate
the pathological mechanism related to S100a9 in AD, we induced
the endogenous expression of S100a9 in the microglia cell line, BV2
cells. After transfection with CT50 or CT99 in murine BV2
microglia cells, the gene expression of S100a9 was verified by RT-
PCR. We found that the mRNA level of S100a9 was significantly
increased in transfectants of CT50 or CT99 at 48 h and 72 h after
transfection, especially at 48 h (Figure 2B). Ab or CT could induce
S100a9 via regulation of S100a9 promoter activity. We examined
this possibility with a promoter activity assay. At 48 h post-
transfection, the transactivational effect of CT50 and CT99 on
S100a9 promoter activity was assessed (1.5860.32 by CT50,
2.0960.32 by CT99; Figure 2C). The effects of wild-type APP
(wtAPP) and Swedish type APP (sweAPP) on S100a9 promoter
activity werealsomeasured (1.4360.41by wtAPP, or 1.3560.20 by
sweAPP),and especially, CT99 strongly increasedS100a9promoter
activity (Figure 2C). Next, treatments with various concentrations of
Ab or CT peptides (1, 10 mMo fC To r2 ,2 0mMo fA b) for 48 h
induced mRNA level of S100a9 in a dose-dependent manner
(Figure 2D). 10 mM CT significantly increased the mRNA level of
S100a9 [ratio=2.1560.29, p=0.0048 versus NC (negative con-
trol), student’s t-test] (Figure 2E).Immunocytochemical analysisalso
showed that S100a9 was induced by Ab or CT peptides in a dose-
dependent manner (Figure 2F).
S100a9 Induced by Ab or CT Increases the Intracellular
Calcium Level in BV2 Cells
As it has been reported that micromolar concentrations of S100
protein increase intracellular calcium ([Ca
2+]i) levels [24], we
hypothesized that CT induced the S100a9 gene, leading to
increased [Ca
2+]i levels.
In BV2 cells treated with 0.1, 1 and 10 mM CT peptides or 1
and 10 mMA b peptides for 48 h, [Ca
2+]i levels were evaluated
using the Fluo3/AM method. [Ca
2+]i levels were increased in a
dose-dependent manner and their increases relative to control
(ratio) were calculated (Figures S2A&B). 10 mM CT significantly
increased the level of [Ca
2+]i (Figure S2B).
To determine whether S100a9 increased the [Ca
2+]i levels, we
delivered S100a9 small interfering (si) RNA (si-S100a9) into BV2
cells treated with CT peptides. Knockdown of the S100a9 gene
reduced the expression of S100a9 (Figure 3D) and significantly
attenuated the increase of [Ca
2+]i levels by CT (from ra-
tio=12.6360.65 to ratio=1.4960.45, p=0.00016 versus si-
CTL/CT 10 mM, Student’s t- test). si-CTL did not affect the
[Ca
2+]i level (Figures 3A&B).
We also investigated the levels of [Ca
2+]i by Ab treatment in
combination with si-S100a9 and knockdown of the S100a9 gene
significantly attenuated the increase in [Ca
2+]i levels by 10 mMo f
Ab (from ratio=3.3160.58 to ratio=1.0260.20, p=0.0086
versus si-CTL/Ab 10 mM, Student’s t- test) (Figure S3).
Proinflammatory Cytokines Are Increased in BV2 Cells
Treated with Either Ab or CT Peptides
The increase of [Ca
2+]i may initiate the inflammatory response
in activated microglia [25]. Here, we found that either Ab or CT
treatment significantly increased the proinflammatory cytokines,
IL-1b and TNF-a, in a dose-dependent manner (Figure 3C). To
test the effects of S100a9 induction on the production of
proinflammatory cytokines, S100a9 was silenced with si-S100a9.
We found that the levels of IL-1b and TNF-a induced by CT were
reduced by 60% with si-CTL, as was the expression of S100a9
(Figure 3D). The increased level of iNOS by CT was also reduced
to about 70% by si-S100a9 (Figure 3D). As shown in Figure 3E,
silencing of the S100a9 gene significantly attenuated CT-induced
nitric oxide (NO) release (10 mM for 48 h) from 21.2962.78 (mM)
to 3.1960.88 (mM).
S100a9 Knockdown Attenuates Learning and Memory
Impairment in Tg2576 Mice
To explore the role of S100a9 in AD pathogenesis, we injected
S100a9 lentiviral short hairpin RNA (sh-S100a9) or control
lentiviral short hairpin RNA (sh-CTL) into the brains of 13-
month-old Tg2576 and age-matched wild-type mice. Two months
later, we evaluated learning and memory impairment in the
Morris Water Maze task in sh-S100a9 or sh-CTL-injected mice.
Tg2576 mice injected with sh-S100a9 (Tg_sh-S100a9) showed a
significant difference from the Tg_sh-CTL group on the 6
th day of
the learning sessions (p=0.0055, F=4.49; Figure 4A). We found
no noticeable differences between the WT_sh-CTL and WT_sh-
S100a9 groups (Fig. 4A). To confirm that the memory impairment
in Tg2576 mice was actually improved by sh-S100a9 injection, we
performed the probe test 48 h after the final trial and recorded the
duration of time spent in zone 4 without the platform. Similar to
the WT group, Tg_Sh-S100a9 mice stayed significantly longer in
zone 4 than in the other zones (zones 1–3) (Figure 4B). However,
there was no significant difference for Tg_sh-CTL mice in terms of
time spent in different zones, and no noticeable difference in the
WT mice treated with sh-S100a9 or sh-CTL (Figure 4B). These
data show that S100a9 knockdown increased the spatial reference
memory in Tg2576 mice.
Treatment with sh-S100A9 Reduced the Number of
Amyloid Plaques and Eosinophilic Pyknotic Neurons in
Tg2576 Mice Brains
To investigate possible links between the severities of memory
impairment and amyloid deposition, we examined amyloid plaque
load and the protein levels of Ab and CT in the brains of 15-
month-old WT_sh-CTL, WT_sh-S100a9, Tg_sh-CTL and
Tg_sh-S100a9 mice (i.e., after behavioral tests) using 6E10
antibody, which specifically recognizes amino acids 1–17 of the
Ab region. In the brain sections of Tg_sh-CTL mice, amyloid
plaques were highly stained by 6E10 antibody in the cortex and
hippocampal region (Figure 5A). Dense-cored plaques of amyloid
were detected in brain sections of Tg_sh-CTL mice. However, the
number of amyloid plaques in Tg_sh-S100a9 mice was signif-
icantly reduced (from 20.1562.24 to 11.461.34, P=0.001,
Student’s t-test; Figure 5B). In the brains of WT mice, few or no
amyloid plaques were observed (Figures 5A&B). We then
confirmed these data by quantifying the size and density of each
amyloid plaque (Figure 5C). For detection of amyloid plaques,
Congo red staining was also performed and Congo-red stained
plaques concurred with Ab immunoreactive plaques (Figure 5Aj).
Serial brain sections were also labeled with S100a9 antibodies.
Lentiviral sh-S100a9 significantly reduced S100a9 expression in
the brains of Tg_sh-S100a9 mice (data not shown). In both the
cortex and hippocampus from mouse brains in each group,
S100a9 expression was increased in the Tg_sh-CTL group and
significantly decreased in the Tg_sh-S100a9 group compared with
The Roles of S100a9 in AD
PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8840Figure 2. Ab and CT induced S100a9 expression in BV2 cells. (A) Immunostaining for S100a9 (green) and CD11b (red) was performed in the
cortex and CA3 of Tg and wild-type mouse brains. DAPI (blue) staining indicates the nuclei. Scale bars represent 20 mm. WT and Tg represent wild-
type control and transgenic animals, respectively. (B) The mRNA levels of S100a9 were checked at 24 h, 48 h, and 72 h post-transfection with CT50 or
CT99 by RT-PCR. (C) Human S100a9 promoter in pGL3 vector was cotransfected with CT, wtAPP or sweAPP in pcDNA vector and fe65 into SHSY5Y
cells. 48 h after transfection, luciferase reporter assays were performed for CT50, CT99, wtAPP and sweAPP, the four S100a9 targets. Luciferase
activities were normalized versus the obtained protein concentrations. The histogram shows the ratio of luciferase activity in transfected cells to
empty vector-transfected cells (n=5). (D) RT-PCR of S100a9 induced at 48 h post-treatment with 1 mM and 10 mMC To r2mM and 20 mMA b. (E) The
quantification of RT-PCR normalized to actin (n=8). (F) Immunocytochemistry; BV2 cells grown on a glass coverslip were treated with CT (5 mM and
10 mM) and Ab (20 mM) for 48 h. S100a9-positive cells were visualized with FITC (green)-conjugated secondary antibodies. Nuclei were counter-
stained with DAPI (blue). Scale bars represent 20 mm. All data are presented as the means6SEM. *P,0.05, **P,0.01 by Student’s t –test.
doi:10.1371/journal.pone.0008840.g002
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PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8840Figure 3. S100a9 induced by Ab or CT increased [Ca
2+]i level and proinflammatory cytokines in BV2 cells. (A) [Ca
2+]i images obtained by
Fluo3 AM at 48 h after treatment with 10 mM CT and 20 nM si-S100a9 in BV2 cells. Scale bars represent 50 mm. si-CTL is a control containing the
scrambled sequence of S100a9 (B) The histogram shows the ratio of [Ca
2+]i levels to NC group. [Ca
2+]i levels in BV2 cells treated with CT and si-S100a9
was compared to that in BV2 cells with CT and si-CTL (control) (n=5). (C) After treatment with 1, 5, or 10 mM CT and 5 or 10 mMA b to BV2 cells, the
levels of the pro-inflammatory cytokines, IL-1b and TNF-a, were measured by western blotting. The membrane was stripped and reprobed with
GAPDH to confirm equal loading and with 6E10 antibody to confirm intracellular CT and Ab. (D) At 48 h post-treatment with si-S100a9, expressions of
S100a9, IL-1b, TNF-a and iNOS were attenuated. The membrane was stripped and reprobed with GAPDH to confirm equal loading. (E) At 48 h post-
treatment with 10 mM CT and si-S100a9, NO release (mM) was measured by Griess reagent. LPS (1 mg/ml) was used as a positive control. All data are
presented as the means 6 SEM (n=10). NC: negative control (non-treated cell) **P,0.01, ***P ,0.001 by Student’s t -test and one-way ANOVA.
doi:10.1371/journal.pone.0008840.g003
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between WT_sh-CTL and WT_sh-S100a9 animals (Figure 5D).
The expression of APP was not changed between Tg_sh-S100a9
and Tg_sh-CTL mice, but, interestingly, the levels of Ab and CT
were decreased in the Tg_sh-S100a9 (Figure 5D), consistent with
the decreased number of amyloid plaques (Figures 5A–C). These
results suggest that S100a9 might be a contributing factor to
increase Ab and CT in Tg2576 mice. Therefore, we determined
the effect of S100a9 on neprilysin, the Ab-degrading enzyme, and
measured the expression of neprilysin in the brains of each group.
Neprilysin levels in Tg2576 mice were significantly reduced to
about 40% of that in age-matched WT mice. However, neprilysin
levels in Tg_sh-S100a9 mice were similar to those of WT mice
(Figure 5D).
Eosinophilic pyknotic neurons suggesting neuronal degenerative
changes were observed by hematoxylin and eosin (H&E) staining.
In the serial brain sections of Tg_sh-S100a9 mice, the number
of eosinophilic pyknotic neurons was reduced in cortex and
hippocampal regions (CA3, DG) of the brain compared with that
in the brains of Tg_sh-CTL mice (Figure S4). However, few
eosinophilic pyknotic neurons were observed in the comparative
regions of the WT_sh-CTL and WT_sh-S100a9 groups. Thus,
these experiments indicate that S100a9 might be related to
neurodegeneration in the AD animal model, Tg2576 mice.
Discussion
The induction of the S100a9 gene was found in the brains of
AD patients and AD animal models, Tg2576 and CT-Tg mice.
From these results, we concluded that S100a9 might be involved in
the pathogenesis of AD. Recently, S100a9 has been proposed to
participate in the inflammation of AD pathogenesis [16], but the
detailed molecular mechanism of these pathological events
remains unknown. Therefore, we focused on the role of S100a9
in the neuroinflammation related to AD.
In this study, prominent staining of S100a9 was detected in the
microglia of CT-Tg mice. In BV2 cells transfected with either
CT50 or CT99 or treated with either Ab or CT, the induction of
S100a9 was confirmed at the mRNA and protein levels. In the
luciferase promoter assay, the promoter of S100a9 gene was
Figure 4. Treatment with shRNA-S100a9 attenuated learning and memory impairment in Tg2576 mice. (A) Morris water maze task was
performed 2 months after lentiviral infection. The task was conducted for 9 consecutive days. A significant difference was observed between the
Tg_sh-S100a9 group and the Tg_sh-CTL group from the 6
th day of the Morris water maze task. (B) The probe test was carried out 48 h after the final
trial. Tg_sh-S100a9 group showed memory improvement compared to Tg_sh-CTL in zone 4 where the platform had been hidden (n=8 per group).
**P,0.01, ***P,0.001 by one-way ANOVA.
doi:10.1371/journal.pone.0008840.g004
The Roles of S100a9 in AD
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8840Figure 5. S100a9 knockdown reduced the number of amyloid plaques in Tg2576 mouse brains. At 2 months after lentiviral infection,
immunostaining and western blot analyses were performed. (A) Immunostaining with 6E10 antibody for the detection of amyloid plaque in the
mouse brain of Hippocampus (Hippo) and Cortex. Higher-magnification view of box in (g) is shown in (i). (j) is Congo red stained image of (i). Scale
bars represent 200 mm in (d&h) and 50 mm in (i&j). (B) The number of plaques was counted in whole brain of each group (n=10). ***P ,0.001 by
Student’s t- test (C) Size and density of plaques was measured by Multi-Gauge program (version 3.0) in whole brain of each group (n=10). Results are
presented as the means of (QL-BG) 6 SEM. **P,0.01 by Student’s t- test. (D) Western blot analysis was performed with total lysates from the cortical
region (a) or hippocampus region (b) of the brains in each group using C9 for APP and CT, 6E10 for Ab, anti-Neprilysin or anti-GAPDH antibody. All
data represent the means 6 SEM from at least five independent experiments.
doi:10.1371/journal.pone.0008840.g005
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significantly induce S100a9 expression by direct or indirect
regulation of S100a9 promoter activity. A number of distinct
regulatory regions and binding partners of S100a9 have been
verified in the nervous system [2,26,27]. In particular, C/EBPa
and C/EBPb have been shown to bind 1 kb upstream of S100a9
promoter, leading to the transcription of the S100a9 gene [27].
Tip60, which is one of transcription factor for the transregulation
of CT [21,28], has been proposed to be a co-activator of C/EBPa
[29], suggesting that CT might induce S100a9 expression through
interactions with Tip60 and C/EBPa in the nucleus. Although Ab
cannot activate gene transcription through nuclear translocation
and direct binding to the transcription factor, Ab may induce
S100a9 transcription through activation or suppression of
signaling molecules such as CREB (cAMP response element
binding protein), BDNF (brain-derived neurotrophic factor) or
CaN (calcineurin). Ab has been reported to promote CaN-
dependent CREB dephosphorylation or suppress the activation of
BDNF, interfering with neuronal function and contributing to
cognitive deficit in AD before the onset of massive neuronal
degeneration [30,31].
In calcium imaging assays, we found that Ab or CT significantly
increased [Ca
2+]i levels in BV2 cells, while silencing of the S100a9
gene reduced the increased [Ca
2+]i levels by Ab or CT to the
control levels. We hypothesized that Ab or CT increased the
expression of S100a9, leading increased [Ca
2+]i levels [24].
Microglia from AD brains had a higher [Ca
2+]i level than control.
This elevated [Ca
2+]i level proves some executive functions of
activated microglia in the pathogenesis of AD [25]. Activated
microglia can proliferate, actively migrate to the site of injury, and
release a variety of factors such as cytokines, chemokines, NO, and
growth factors to affect the pathologic processes [32]. Here, we
show that either Ab or CT treatment induced significant increases
of pro-inflammatory cytokines, IL-1b, TNF-a and iNOS in BV2
cells. But, treatment with si-S100a9 attenuated the increase of
IL-1b, TNF-a and iNOS by CT. The induction of NO by CT was
also greatly reduced by si-S100a9 treatment, suggesting that
S100a9 is critical for the inflammatory response induced by CT.
Our results suggest that S100a9 might induce the neuroinflamma-
tion by increasing the [Ca
2+]i level, although it cannot be excluded
that S100a9 might affect both processes independently. We
investigated the levels of other specific calcium-binding proteins,
calbindin D-28K and other S100 proteins, S100a8 and S100B in
Tg2576 mice brains. Our data indicate that calbindin D-28K,
S100a8 and S100B are not induced in the Tg2576 mice brains
compared with those in the wild type mice brains (Figure S5). And
also there is no change in their levels between Tg_sh-CTL group
and Tg_sh-S100a9 group (Figure S5). We assume that calcium
dyshomeostasis are mainly induced by S100a9.
Here, we provide in vivo evidence that the up-regulation of
S100a9 in the brains of Alzheimer’s patients and an animal model
of AD might be related to the pathogenesis of AD. Increased
S100a9 expression might contribute to the impairment in synaptic
plasticity and cognitive function as well as neurodegeneration. In
this study, S100a9 knockdown was performed using S100a9
lentiviral short hairpin RNA in the brains of 13-month-old
Tg2576 mice and age-matched wild-type mice. Two months after
injection, we observed reduced S100a9 expression in both the
cortex and hippocampus in the brains of Tg_sh-S100a9 mice. The
Morris water maze task clearly showed that S100a9 knockdown
restored the learning and memory function in Tg2576 mice.
Memory dysfunction was severe in the Tg_sh-CTL group. In a
previous study of Tg2576 mice, spatial memory loss coincided
with the appearance of aggregated Ab [22], and diffuse plaques,
and biochemically extracted Ab42 and Ab40 were increased to
levels like those observed in AD brains [33]. The presence of
amyloid plaques containing predominantly Ab and neurofibrillary
tangles is believed to be a pathological feature of AD [1,18]. Our
data showed that S100a9 knockdown markedly reduced the
number of amyloid plaques in Tg2576 mice brain. We also found
that the levels of Ab and CT were decreased in the brains of
Tg_sh-S100a9 mice compared with those in Tg_sh-CTL mice.
A recent report showed that microglia in the brains of aged AD
mice became dysfunctional in terms of Ab clearance, and
expressions of their Ab-binding receptors and Ab-degrading
enzymes were significantly reduced; however, their ability to
produce proinflammatory cytokines was maintained [34]. In our
results, the level of the Ab-degrading enzyme, neprilysin, was
decreased in the brains of Tg2576 mice. However, S100a9
knockdown recovered the level of neprilysin to that of WT mice.
These results suggest that S100a9 might play a role in APP
metabolism by down-regulating neprilysin in the brains of Tg2576
mice. We also suggest that overproduction of Ab or CT induced
by an increase of S100a9 might accelerate neuronal degeneration.
In fact, we found that the number of eosinophilic neurons in
hippocampus was increased in the brains of Tg2576 mice, but was
significantly reduced in Tg_sh-S100a9 mice. These findings
strongly suggest that an increase in S100a9 may be closely related
to the pathogenesis of AD.
Altogether, we demonstrate with these data that S100a9 is
induced by either Ab or CT, leading to the pro-inflammatory
response and resulting in neuronal death. Also, S100a9 might be
responsible for the production and accumulation of CT/Ab
through the regulatory protein like neprilysin in the brains of
Tg2576 mice. Finally, S100a9 gene silencing significantly reduced
AD pathology, including the number of plaques, and improved the
learning ability of Tg2576 mice. Therefore, inhibition of S100a9
may be an alternative AD therapeutic design.
Materials and Methods
Sample Preparation and Microarray Analysis
We used brains of the transgenic mice (11months) model
expressing the familial Alzheimer’s disease (FAD) as making V717I
(valine to isoleucine) ‘London’ mutation within an APP-CT99
which encompasses the b amyloid (Ab) sequence. APPV717I-
CT100 Tg mice were provided from Dr. Emson PC at Babraham
institute. We extracted total RNA of hippocampus in three brains
of 11 month-old APPV717I-CT100 Tg mice. Total RNA was
prepared from using Trizol reagent (invitogen). All the microarray
experiments were done with CodeLink Twinchip
TM Mouse-20K
(Amersham Bioscience) from Digital Genomics (Seoul, South
Korea). Processed slides were scanned using an Axon GenePix
4000B Scanner with the laser set to 635 nm, the photomultiplier
tube (PMT) voltage to 600 and the scan resolution to 10 mm.
Images for each slide were analyzed using the CodeLink
TM
Expression Analysis Software v4.1(GE Healthcare Life Science).
Genes showing significant expression changes (.2 fold) were
selected with a cutoff of 5% of a q value. The Microarray dataset
are deposited at Gene Expression Omnibus (GEO) database and
are accessible through accession number (GSE18762).
Human AD Brains
Paraffin-embedded brain stocks and the frozen tissues of from
69 to 87 years old-AD and age-matched control subjects were
obtained from the Netherlands Brain Bank (NBB). In AD tissues,
the neuropathological diagnosis is Alzheimer’s disease (AD) and
Braak & Braak stage V or VI. The neuropathological diagnosis of
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Coronal sections (4 mm) were cut through the hippocampus and
processed for immunohistofluorescence. For western blot analysis,
we used the frozen tissues of the brain. All experimental
procedures were performed in accordance with ‘the Guidelines
of the Ethics Committee at Seoul National University’.
Cell Culture
The BV2, immortalized murine microglial cell line, was
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Life
Technology) supplemented with 5% fetal bovine serum (Hyclone)
and penicillin/streptomycin (100 U/ml/100 mg/ml) (Life Tech-
nology) at 37uC and 5% CO2
RT-PCR
Total RNA (2 mg) isolated from brain tissues or cells with Trizol
reagent (invitrogen) was used for cDNA synthesis by AccuPower
RT premix (Bioneer). The abundance of transcripts in cDNA
samples was measured by RT-PCR with primer as follows: S100a9
forward, 59- CAGCATAACCACCATCATCG-39, reverse, 59-G-
TCCTGGTTTGTGTCCAGGT-39; actin forward, 59-CCA-
GATCATGTTTGAGACCT-39, reverse, 59-GTTGCCAATAG-
TGATGACCT-39. The PCR reactions were subjected to 40
cycles of PCR amplification (95uC for 1 min, 58uC for 1 min,
72uC for 1 min). All results were normalized to actin.
Antibodies
Anti-APP C-terminal polyclonal antibody (C9) was purchased
from Chemicon (California); 6E10 (Chemicon), CD11b (Chemi-
con), IL-1b (R&D), TNF-a (R&D), iNOS (Santa Cruz), anti-
S100a9 (R&D), anti-GAPDH (Santa Cruz), anti-tubulin (Santa
Cruz), Neprilysin (alpha diagnostic).
Western Blot Analysis
Cells or tissues were washed with phosphate buffered saline
(PBS) and lysed in RIPA buffer with cocktail of protease inhibitors
(Roche). Proteins were separated by SDS-PAGE and transferred
to a PVDF membrane. The PVDF membrane was blocked with
5% nonfat dry milk in Tris-buffered saline. After 1 h blocking, the
protein blot was confirmed with appropriate antibodies and
detected using horseradish peroxidase-conjugated secondary
antibody (Amersham Pharmacia).
DNA Construct and Transfection
The CT50 and CT99 constructs in these experiments were
previously reported in Chang et al.[19]. Briefly, CT50 or CT99 to
encompass the last 50 or 99 amino-acid residues of human
APP695 cDNA was subcloned into a pcDNA3-flag vector with the
flag at the N-terminus. Cells were transiently transfected with
individual constructs by using Fugene 6 according to the
manufacturer’s instruction (Roche, Germany).
Luciferase Assay
Human S100a9 promoter in pGL3 vector provided from Dr.
Claus Kerkhoff at university of Muenstet in Germany were
cotransfected with CT, wtAPP or sweAPP in pcDNA vector and
fe65 into SHSY5Y cells. After 48 h transfected, the cells were lysed
by Luciferase Assay system with reporter lysis buffer (Promega,
WI, USA). Luciferase activity was measured using a Biocounter
M1500 luminometer (Lumac, GE Groningen, Netherlands).
Protein concentrations were determined using Bradford protein
assay reagent (Bio-Rad), and luciferase activities were normalized
versus the obtained protein concentrations.
Preparation and Treatment of CT and Ab Peptide
The expression plasmid pET28a-CT99 tagging His was
constructed by ligating CT99 digested with NdeI and BamHI
into pET28a and transformed into Escherichia Coli. CT99 (CT)
peptide was purified by Ni-NTA superflow (Qiagen) and then
dialyzed against 10 mM Tris-HCl (pH 7.4), followed by lyophi-
lization. We used synthetic Ab1–42 (Ab) peptide with .95% pure
by RPHPLC chromatography (Sigma). Ab peptide was dissolved
to 1 mmol/L in 100% hexafluoroisopropanol (Sigma). Hexafluor-
oisopropanol was removed under vacuum, and the peptide was
stored at 220uC. For the aggregation, the peptide was first
resuspended in dry dimethylsulfoxide (DMSO; Sigma) to 5 mmol/
L. For oligomeric conditions, F-12 (without phenol red) culture
medium was added to bring the peptide to a final concentration of
200 mmol/L, and the peptide was incubated at 4uC for 24 h[35].
Calcium Level Measurement Using Fluo-3/AM
BV2 cells were plated and cultured on glass coverslips coated
with 10 mg/ml PEI (Polyethylenimine). The cells, pretreated with
various dose of CT and Ab peptide, were washed twice with
Hank’s solution (Gibco) and incubated for 20 min at 37uC in the
same buffer containing 10 mM Fluo-3/AM. After mounting the
cells, its images were obtained using a laser-scanning confocal
microscope (Zeiss). Excitation was achieved using an Argon ion
laser (wavelength (l) =488 nm) and fluorescence was measured
at l.515 nm. Changes of [Ca
2+]i levels were measured using
relative fluorescence compared with that of control group.
siRNA Treatment
A siRNA oligonucleotide targeting the mouse S100a9 mRNA
(si-S100a9) was designed from Qiagen. BV2 cells were seeded in
six-well plates at 2610
5 cells/well and incubated overnight at
37uC. Then cells were transfected with 20 nM of siRNA using
HiPerFect (Qiagen) as directed by the manufacturer. We treated
CT peptide at 12 h post transfection siRNA. Cells were incubated
for 48 h after transfecting siRNA.
Assay for Nitric Oxide (NO) Derivatives
NO2 accumulation in the medium was used as an indicator of
NO production. Nitric oxide induced by CT was measured by
Griess reagent (G4410, Sigma). After the appropriate incubation
time with the peptides on the BV2 cell, supernatant was harvested,
and then mixed with equal volumes of 1xGreiss Reagent and
sample (working range: 0.43,0.65 mmolar nitrite) in the 96well
plate. Spectrophotometric absorbance was measured at 540 nm
after 5 min. The values measured were compared with the vehicle
control.
Immunohistochemistry
Mice brains and human AD brains in 10% neutral buffered
formalin for 48 h were dehydrated and embedded in paraffin.
Before immunostaining, slides were deparaffinized in xylene
and then dehydrated through graded alcohols to water. The
fluorescent immunohistochemistry was performed with appropri-
ate primary antibodies at 4uC for O/N and visualized using Cy3-
conjugated or FITC-conjugated secondary antibody (Jackson,
West Grove, Pennsylvania). DAPI counter staining was per-
formed. Images were collected using the LSM 510 program on a
Zeiss confocal microscope (Carl Zeiss MicroImaging, Inc.).
For the non-fluorecence labeling, Immunohistochemistry was
performed using a Vectastain avidin-biotin complex (ABC) elite
kit. Reaction product was detected using 3,3-diaminobenzidinete-
trahydrochloride (DAB). Photomicrographs were acquired with a
The Roles of S100a9 in AD
PLoS ONE | www.plosone.org 9 January 2010 | Volume 5 | Issue 1 | e8840color digital camera DFC280 (Leica) attached to a microscope
(BX-51; Olympus).
sh-S100a9 Virus Preparation and Production
The sh-S100a9 hairpin oligo (59-CCGGGCTGAGCTTT-
GAGGAGTGTATCTCGAG ATATCACTCCTCAAAGCTC-
AGCTTTTTG-39; Clone ID: NM_009114.1-255s1c1) was select-
ed from five Lentiviral transfer vector of the sh-S100a9 containing
mouse U6 promoter received in bacterial Glycerol Stock by Sigma-
Aldrich (Missouri, USA). The transfer vector plasmid (sh-CTL or
sh-S100a9), together with the packaging construct plasmid
pCMVDR8.2 and the envelope plasmid pVSV-G, were cotrans-
fected into HEK293T cells to produce the viral particles. After
overnight incubation, the medium was changed. Supernatants were
collected from day 2 to 4 post transfection. The viral particles in the
supernatant werefiltered througha 0.45 mm pore sizefilterandthen
sediment by ultracentrifugation at 35,000 rpm, 4uC for 2 h. The
pellets were re-dissolved in PBS. For in vivo experiments, the virus
was further centrifuged for 50,000 rpm 4uC for 2 h and re-dissolved
in PBS, resulting in a final 1,000-fold concentration.
Animal Preparation and Injection of sh-S100a9 into
Tg2576 Mice Brains
APPswe Tg2576 mice were obtained from Taconic Farms
(Germantown, NY) and were bred by mating male mice with
C57B16/SJL F1 females, as recommended by the suppliers and as
described by others [33]. Studies were performed by comparing 13
month-aged heterozygous transgenic (Tg2576) mice from to age-
matched transgene-negative littermates (wild type). Mice were
divided into four groups (8 mice per each group) and each
anaesthetized mouse in WT or Tg group was received 2 ml of the
concentrated sh-CTL or sh-S100a9 virus, respectively using a
Kopf stereotaxic frame (Kopf Instruments, Tujunga, CA), loaded
into the hippocampus (AP, 0.18 mm; ML, 0.20 mm; DV,
0.19 mm) over a period of 5 min and retracted after an additional
5 min. The procedures were overseen by the Animal Care and
Use Committee of Seoul National University.
Morris Water Maze Task
The Morris water maze was performed at 2 months after virus
injection. The experimental apparatus consisted of a circular water
tank (diameter=140 cm; height=45 cm), containing water at
23uC to a depth of 35.5 cm and rendered opaque by adding milk.
A platform (diameter=15 cm; height=35 cm) was submerged
1 cm below the water surface and placed at the midpoint of one
quadrant. The pool was located in a test room containing various
prominent visual cues. Three training trials per day were conducted
for 9 consecutive days, with a rotation order per trial in a group.
Mice were placed in the pool at one of three quadrant starting
positions (except one quadrant containing platform). In each
training trial, the time required to escape onto the hidden platform
was recorded. Mice that found the platform were allowed to remain
on the platform for 30 s and then were returned to the home cage
during the inter-trial interval. Mice that did not find the platform
within 60 s were placed on the platform for 30 s at the end of trial.
After 48 h of the final trial, a single probe trial was conducted. The
escape platform was removed, and each mouse was allowed to swim
for 60 s in the maze. The time spent in the quadrant that previously
contained the platform was recorded as the total time in the pool.
Congo Red Staining
Deparaffinized and hydrated sections were incubated in a
freshly prepared alkaline alcoholic saturated sodium chloride
reagent (2.5 mM NaOH in 80% reagent-grade alcohol) for
20 min at room temperature and then were incubated in 0.4%
Congo red (W/V, Sigma) in an alkaline alcoholic saturated
sodium chloride reagent (freshly prepared and filtered just prior to
use) for 30 min at room temperature. Sections were washed in
distilled water and counterstained with hematoxylin for 1 min.
And then sections were rinsed through ascending grades of ethanol
with a final three changes of 100% reagent-grade ethanol, cleared
in xylene and cover slipped with permount (Fisher Scientific).
Hematoxylin and Eosin Staining
Slides were incubated with Mayer’s hematoxylin (DakoCyto-
mation) and eosin (Acros organics). Sections were dehydrated
through graded alcohols, cleared in xylene, and cover slipped in
Canadian balsam solution.
Statistical Analysis
Statistical analysis was performed by Student’s t-test and
ANOVA using an SASS program (SPSS Inc., Chicago, Ill) to
study the relationship between the different variables. Values of
P,0.05 were considered to indicate statistical significance.
Supporting Information
Figure S1 S100a9 was induced in the brains of Human AD
patients. (A) The level of S100a9 protein was examined in the
hippocampus of AD patients’ brains. Tubulin was used as a
loading control. This is a representative blot (n=10). (B) We
quantified the density of S100a9 with gel doc and normalized it to
that of Tubulin (n=10). *P,0.05 by Student’s t-test.
Found at: doi:10.1371/journal.pone.0008840.s001 (0.85 MB EPS)
Figure S2 [Ca2+]i level induced by Ab or CT in a dose-
dependent manner. (A) BV2 cells grown on glass coverslip for 48 h
were treated with 0.1, 1, or 10 mM CT and 1 or 10 mMA b and
then [Ca2+]i level was measured by Fluo3 AM. Scale bars
represent 50mm. (B) Graph shows the fold-change of relative
fluorescence intensity versus that of control. (n=10). Results are
presented as the means 6 SEM. NC: negative control, **P,0.01,
***P ,0.001 by Student’s t-test.
Found at: doi:10.1371/journal.pone.0008840.s002 (3.68 MB EPS)
Figure S3 S100a9 induced by Ab increased [Ca2+]i level in
BV2 cells. (A) [Ca2+]i mages obtained by Fluo3 AM at 48 h after
treatment with 10 mMA b and 20 nM si-S100a9 in BV2 cells.
Scale bars represent 50mm. si-CTL is a control containing the
scrambled sequence of S100a9 (B) The histogram shows the ratio
of [Ca2+]i levels to NC group. [Ca2+]i levels in BV2 cells treated
with Ab and si-S100a9 was compared to that in BV2 cells with Ab
and si-CTL (control) (n=5). Results are presented as the means 6
SEM. NC: negative control, **P ,0.01 by Student’s t-test.
Found at: doi:10.1371/journal.pone.0008840.s003 (2.34 MB EPS)
Figure S4 S100a9 knockdown reduced the number of eosino-
philic cells in Tg2576 mice brains. At 2 months after lentiviral
infection, Hematoxylin and eosin (H&E) straining was performed
in hippocampus and cortex. Scale bars indicate 100 mm in large
square box and 20 mm in small square box.
Found at: doi:10.1371/journal.pone.0008840.s004 (2.42 MB EPS)
Figure S5 Expression of calcium binding proteins in Tg2576
mouse brains. At 2 months after lentiviral infection, western blot
analysis was performed with total lysates from the cortical region
of the brains in each group using anti-Calbindin D-28K, anti-
S100a8 and anti-S100B antibody. The membrane was stripped
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representative blot from at least five independent experiments.
Found at: doi:10.1371/journal.pone.0008840.s005 (1.19 MB EPS)
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